ATE390441T1 - Niedrigallergene proteinvarianten - Google Patents

Niedrigallergene proteinvarianten

Info

Publication number
ATE390441T1
ATE390441T1 AT02020745T AT02020745T ATE390441T1 AT E390441 T1 ATE390441 T1 AT E390441T1 AT 02020745 T AT02020745 T AT 02020745T AT 02020745 T AT02020745 T AT 02020745T AT E390441 T1 ATE390441 T1 AT E390441T1
Authority
AT
Austria
Prior art keywords
protein
parent protein
immunogenicity
low
parent
Prior art date
Application number
AT02020745T
Other languages
English (en)
Inventor
Erwin Ludo Roggen
Arne Agerlin Olsen
Steffen Ernst
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27221271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE390441(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes As filed Critical Novozymes As
Application granted granted Critical
Publication of ATE390441T1 publication Critical patent/ATE390441T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/02Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0055Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0061Laccase (1.10.3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2408Glucanases acting on alpha -1,4-glucosidic bonds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2408Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411Amylases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y110/00Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03002Laccase (1.10.3.2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02020745T 1998-10-30 1999-10-12 Niedrigallergene proteinvarianten ATE390441T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199801402 1998-10-30
DKPA199801645 1998-11-25
DKPA199901417 1999-10-04

Publications (1)

Publication Number Publication Date
ATE390441T1 true ATE390441T1 (de) 2008-04-15

Family

ID=27221271

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02020745T ATE390441T1 (de) 1998-10-30 1999-10-12 Niedrigallergene proteinvarianten
AT99947260T ATE263778T1 (de) 1998-10-30 1999-10-12 Niedrigallergene proteinvarianten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99947260T ATE263778T1 (de) 1998-10-30 1999-10-12 Niedrigallergene proteinvarianten

Country Status (10)

Country Link
EP (2) EP1277762B1 (de)
JP (1) JP2003500003A (de)
CN (1) CN1206237C (de)
AT (2) ATE390441T1 (de)
AU (1) AU776534B2 (de)
CA (1) CA2348938A1 (de)
DE (2) DE69916306T2 (de)
ES (1) ES2220114T3 (de)
NZ (1) NZ511291A (de)
WO (1) WO2000026230A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
EP1198565A1 (de) * 1999-07-07 2002-04-24 Maxygen Aps Verfahren zur herstellung von modifizierten polypeptiden
CA2394377A1 (en) * 1999-12-09 2001-05-10 Novozymes A/S High throughput screening (hts) assays for protein variants with reducedantibody binding capacity
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
WO2001083559A2 (en) * 2000-04-28 2001-11-08 Novozymes A/S Production and use of protein variants having modified immunogenecity
EP1297123B1 (de) * 2000-06-21 2007-06-06 Novozymes A/S Verfahren zum nachweis von genen von sekretierten proteinen
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
ATE403152T1 (de) * 2000-10-17 2008-08-15 Besst Test Aps Test zum direkten nachweisen einer biologischen zelle in einer körperflüssigkeitsprobe
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2003031981A2 (en) * 2001-10-05 2003-04-17 Novozymes A/S Kit for predicting binding of a specific antibody to a potential immunogen and method of screening
CN101177675B (zh) 2002-02-08 2014-05-21 诺维信公司 肌醇六磷酸酶变体
BR0309576A (pt) 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
EP1504089A2 (de) * 2002-05-16 2005-02-09 Alk Abell A/S Allergenmutanten
ATE494368T1 (de) 2002-10-01 2011-01-15 Novozymes As Polypeptide der gh-61-familie
WO2004078960A1 (en) * 2003-02-26 2004-09-16 Genencor International, Inc. Amylases producing an altered immunogenic response and methods of making and using the same
EP2500423B1 (de) * 2003-02-26 2015-06-17 Danisco US Inc. Amylasen, die eine veränderte immunogene Reaktion bewirken, und Verfahren zu ihrer Herstellung und Verwendung
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
US7727756B2 (en) 2003-03-21 2010-06-01 Novozymes A/S Subtilases
WO2004083362A2 (en) * 2003-03-21 2004-09-30 Novozymes A/S Modification of subtilases using protein modelling based on the jp170 three-dimensional structure
DE602004025576D1 (de) 2003-06-19 2010-04-01 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
US20060236414A1 (en) 2003-06-19 2006-10-19 Novozymes A/S Proteases and methods for producing them
CN102505007B (zh) 2003-06-19 2016-04-20 诺维信公司 蛋白酶
ES2358092T3 (es) 2003-10-10 2011-05-05 Novozymes A/S Variantes de proteasa.
WO2005066339A2 (en) 2004-01-06 2005-07-21 Novozymes A/S Polypeptides of alicyclobacillus sp.
ATE491025T1 (de) 2004-04-02 2010-12-15 Novozymes As Subtilasevarianten mit veränderter immunogenität
ES2380105T3 (es) 2004-06-21 2012-05-08 Novozymes A/S Proteasas de Nocardiopsis
EP2272964A3 (de) 2004-10-04 2011-08-31 Novozymes A/S Polypeptide mit Phytaseaktivität und dafür codierende Polynukleotide
AR050895A1 (es) 2004-10-04 2006-11-29 Novozymes As Polipeptidos que tienen actividad de fitasa y polinucleotidos que los codifican
US8119387B2 (en) 2005-08-16 2012-02-21 Novozymes A/S Polypeptides of strain Bacillus sp. P203
EP1998793A1 (de) 2006-03-22 2008-12-10 Novozymes A/S Verwendung von polypeptiden mit antimikrobieller wirkung
WO2007112739A1 (en) 2006-04-04 2007-10-11 Novozymes A/S Phytase variants
EP2261328B1 (de) 2006-12-21 2013-11-20 Novozymes A/S Lipase-varianten zur pharmazeutischen Verwendung
US8221743B2 (en) 2006-12-22 2012-07-17 Novozymes A/S Use of polypeptides against diseases caused by protozoans
DK2129781T3 (da) 2007-03-26 2014-03-31 Novozymes As Hafnia-phytase
JP5056193B2 (ja) * 2007-06-21 2012-10-24 味の素株式会社 畜肉加工食品又は水産加工食品の製造方法及び畜肉加工食品又は水産加工食品改質用の酵素製剤
WO2010034835A2 (en) 2008-09-26 2010-04-01 Novozymes A/S Hafnia phytase variants
JP5230397B2 (ja) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
US9526768B2 (en) 2014-11-13 2016-12-27 Jennifer Mai Compositions for the treatment of cancer
CN108690841B (zh) * 2018-02-08 2021-10-01 河南科技学院 一种mPEG-Mal5000修饰β-淀粉酶的方法
EP4196575A1 (de) 2020-08-13 2023-06-21 Novozymes A/S Phytasevarianten und polynukleotide zur codierung davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2095852C (en) * 1990-12-05 2001-05-08 Uffe Lovborg Proteins with changed epitopes and methods for the production thereof
HUT70461A (en) * 1992-04-01 1995-10-30 Merck Anc Co Inc Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv invention
JP3475221B2 (ja) * 1994-09-05 2003-12-08 明治乳業株式会社 免疫原性が低下された変異体タンパク質
JPH08289790A (ja) * 1995-01-06 1996-11-05 Leuven Res & Dev Vzw 新規なスタフィロキナーゼ誘導体
WO1998020115A1 (en) 1996-11-04 1998-05-14 Novo Nordisk A/S Subtilase variants and compositions
WO1998020155A1 (en) 1996-11-08 1998-05-14 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Diagnostic methods using cd40 ligand assay
CA2319437C (en) * 1998-01-31 2009-06-16 University Of Arkansas Methods and reagents for decreasing allergic reactions

Also Published As

Publication number Publication date
AU776534B2 (en) 2004-09-16
JP2003500003A (ja) 2003-01-07
DE69916306D1 (de) 2004-05-13
CA2348938A1 (en) 2000-05-11
WO2000026230A1 (en) 2000-05-11
EP1124843A1 (de) 2001-08-22
EP1277762A3 (de) 2003-04-09
EP1277762A2 (de) 2003-01-22
NZ511291A (en) 2003-08-29
WO2000026230A8 (en) 2000-07-20
ATE263778T1 (de) 2004-04-15
AU6078799A (en) 2000-05-22
CN1325404A (zh) 2001-12-05
EP1124843B1 (de) 2004-04-07
EP1277762B1 (de) 2008-03-26
DE69938435D1 (de) 2008-05-08
ES2220114T3 (es) 2004-12-01
DE69916306T2 (de) 2005-05-04
CN1206237C (zh) 2005-06-15

Similar Documents

Publication Publication Date Title
ATE263778T1 (de) Niedrigallergene proteinvarianten
DE60322188D1 (de) Zytokin (zcytor17-ligand)
ATE441666T1 (de) Antikírper gegen den fibroblastenwachstumsfaktor 23
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
IT1227907B (it) Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento
ATE446104T1 (de) Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor
DK1501936T3 (da) Familie af cytokin-proteiner
DK1114156T3 (da) Transformerende vækstfaktor Beta-9 (ZTGFSS9) fra pattedyr
DK1908772T3 (da) Polypeptider og polynucleinsyrer af phorphorymonas gingivalis
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
DK0635025T3 (da) Fremgangsmåde til fremstilling af modificerede proteiner
DE69929454D1 (de) Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
CA2441187A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
WO1996002572A3 (fr) Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci
DK0779297T3 (da) Antigene peptider med glycinsubstitutioner
WO1994025594A3 (en) Cloning, expression and vaccine composition corresponding to a peptide antigen of toxoplasma gondii
AU2001277717A1 (en) Novel proteins and dnas thereof
IT9067703A0 (it) Peptidi sintetici contenenti sequenze di aminoacidi che definiscono epitopi immunoreattivi contro anticorpi umani anti hcv, utili per l'alletimento di dosaggi immunologici.
RU97117935A (ru) Свойства пептидов, стимулирующих рост

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties